Showing 8 posts of 8 posts found.


FDA grants ODD to ABM Therapeutics’ treatment for patients with glioblastoma

August 3, 2023
Medical Communications ABM Therapeutics, ABM-1310, FDA, Oncology, glioblastoma

ABM Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ABM-1310. …


Scorpion venom added to CAR-T therapy increases efficacy in brain cancer, research shows

March 6, 2020
Medical Communications, Research and Development CAR-T, Cancer, brain cancer, glioblastoma, pharma

Chimeric antigen receptor T cell (CAR-T) therapy has gained much traction and attention in the past years for its innovative …

MS drug boosts effectiveness of cancer therapy in treating glioblastoma, study shows

August 9, 2019
Medical Communications MS, brain cancer, glioblastoma, oncology, pharma

The multiple sclerosis (MS) drug teriflunomide boosts the effectiveness of cancer drugs in treating glioblastoma, according to researchers from UC, …


AbbVie terminates Phase 3 brain cancer study after Depatux-M shows no benefit

May 20, 2019
Research and Development, Sales and Marketing AbbVie, Cancer, Depatux-M, glioblastoma, pharma, trial failure

AbbVie has terminated a Phase 3 study of the efficacy of Depatux-M (depatuxizumab mafodotin) in the treatment of newly diagnosed …


VBL Therapeutics’ shares plummet on Phase 3 glioblastoma failure

March 9, 2018
Medical Communications, Research and Development VBL, VBL Therapeutics, glioblastoma, pharma, trial failure

Israeli drug development firm VBL Therapeutics has been left reeling after it announced that its lead oncology product ofranergene obadenovec, …


ImmunoCellular awarded $19.9 million grant for ICT-107 phase 3 trial for glioblastoma

September 25, 2015
Research and Development California Institute for Regenerative Medicine, Cancer, ICT-107, brain cancer, glioblastoma

ImmunoCellular Therapeutics has been awarded a $19.9 million grant by California Institute for Regenerative Medicine (CIRM), California’s stem cell agency, …

Merck KGaA readies phase III brain cancer trial

June 13, 2011
Research and Development Merck KGaA, brain cancer, cilengitide, glioblastoma

Merck KGaA has completed patient enrollment for a phase III global trial of its first-in-class integrin inhibitor in a rare …

Brain cancer vaccine to move into phase III

November 24, 2010
Research and Development, Sales and Marketing Celldex, Pfizer, brain cancer, glioblastoma

Celldex will press ahead with large-scale trials of its vaccine treatment for brain cancer after encouraging phase II results. The …

Latest content